Cellebrite DI [CLBT] vs Shift4 Payments [FOUR] Detailed Stock Comparison
Cellebrite DI
NASDAQ
Loading...
Shift4 Payments
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Cellebrite DI wins in 7 metrics, Shift4 Payments wins in 12 metrics, with 0 ties. Shift4 Payments appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Cellebrite DI | Shift4 Payments | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 69.09 | 33.82 | Shift4 Payments |
| Price-to-Book Ratio | 9.55 | 9.84 | Cellebrite DI |
| Debt-to-Equity Ratio | 5.47 | 186.68 | Cellebrite DI |
| PEG Ratio | 39.88 | -0.83 | Shift4 Payments |
| EV/EBITDA | 46.15 | 13.52 | Shift4 Payments |
| Profit Margin (TTM) | -34.56% | 6.11% | Shift4 Payments |
| Operating Margin (TTM) | 14.58% | 9.16% | Cellebrite DI |
| EBITDA Margin (TTM) | 14.58% | 9.16% | Cellebrite DI |
| Return on Equity | -81.98% | 18.28% | Shift4 Payments |
| Return on Assets (TTM) | 5.95% | 3.61% | Cellebrite DI |
| Free Cash Flow (TTM) | $121.56M | $310.60M | Shift4 Payments |
| 1-Year Return | -6.01% | 12.33% | Shift4 Payments |
| Price-to-Sales Ratio (TTM) | 8.93 | 2.20 | Shift4 Payments |
| Enterprise Value | $3.44B | $8.23B | Shift4 Payments |
| EV/Revenue Ratio | 7.88 | 2.28 | Shift4 Payments |
| Gross Profit Margin (TTM) | 84.39% | 30.27% | Cellebrite DI |
| Revenue per Share (TTM) | $2 | $52 | Shift4 Payments |
| Earnings per Share (Diluted) | $-0.72 | $2.66 | Shift4 Payments |
| Beta (Stock Volatility) | 1.27 | 1.81 | Cellebrite DI |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Cellebrite DI vs Shift4 Payments Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Cellebrite DI | 1.26% | 3.27% | 12.97% | -3.59% | -14.99% | -25.62% |
| Shift4 Payments | 2.68% | 0.31% | -14.66% | 4.10% | -6.04% | -15.89% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Cellebrite DI | -6.01% | 235.83% | 66.87% | 66.87% | 66.87% | 66.87% |
| Shift4 Payments | 12.33% | 98.50% | 77.50% | 171.71% | 171.71% | 171.71% |
Performance & Financial Health Analysis: Cellebrite DI vs Shift4 Payments
| Metric | CLBT | FOUR |
|---|---|---|
| Market Information | ||
| Market Cap | $3.90B | $7.96B |
| Market Cap Category | Mid cap | Mid cap |
| 10 Day Avg. Volume | 3,165,587 | 1,805,157 |
| 90 Day Avg. Volume | 2,043,326 | 1,982,786 |
| Last Close | $16.11 | $91.13 |
| 52 Week Range | $13.10 - $26.30 | $68.09 - $127.50 |
| % from 52W High | -38.75% | -28.53% |
| All-Time High | $26.30 (Feb 03, 2025) | $127.50 (Feb 17, 2025) |
| % from All-Time High | -38.75% | -28.53% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.18% | 0.17% |
| Quarterly Earnings Growth | 0.18% | -0.13% |
| Financial Health | ||
| Profit Margin (TTM) | -0.35% | 0.06% |
| Operating Margin (TTM) | 0.15% | 0.09% |
| Return on Equity (TTM) | -0.82% | 0.18% |
| Debt to Equity (MRQ) | 5.47 | 186.68 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $1.67 | $9.14 |
| Cash per Share (MRQ) | $1.93 | $44.14 |
| Operating Cash Flow (TTM) | $161.08M | $512.00M |
| Levered Free Cash Flow (TTM) | $122.92M | $417.24M |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Cellebrite DI vs Shift4 Payments
| Metric | CLBT | FOUR |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 69.09 | 33.82 |
| Forward P/E | 39.88 | 18.70 |
| PEG Ratio | 39.88 | -0.83 |
| Price to Sales (TTM) | 8.93 | 2.20 |
| Price to Book (MRQ) | 9.55 | 9.84 |
| Market Capitalization | ||
| Market Capitalization | $3.90B | $7.96B |
| Enterprise Value | $3.44B | $8.23B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 7.88 | 2.28 |
| Enterprise to EBITDA | 46.15 | 13.52 |
| Risk & Other Metrics | ||
| Beta | 1.27 | 1.81 |
| Book Value per Share (MRQ) | $1.67 | $9.14 |
Financial Statements Comparison: Cellebrite DI vs Shift4 Payments
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | CLBT | FOUR |
|---|---|---|
| Revenue/Sales | $113.28M | $848.30M |
| Cost of Goods Sold | $17.68M | $591.30M |
| Gross Profit | $95.60M | $257.00M |
| Research & Development | $28.61M | N/A |
| Operating Income (EBIT) | $14.42M | $21.70M |
| EBITDA | $17.01M | $121.10M |
| Pre-Tax Income | $20.79M | $11.40M |
| Income Tax | $1.32M | $-8.10M |
| Net Income (Profit) | $19.48M | $19.50M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | CLBT | FOUR |
|---|---|---|
| Cash & Equivalents | $90.48M | $1.17B |
| Total Current Assets | $523.48M | $1.84B |
| Total Current Liabilities | $287.80M | $1.36B |
| Long-Term Debt | $6.39M | $2.18B |
| Total Shareholders Equity | $363.49M | $1.02B |
| Retained Earnings | $-147.46M | $-259.60M |
| Property, Plant & Equipment | $28.03M | $334.80M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | CLBT | FOUR |
|---|---|---|
| Operating Cash Flow | $28.07M | $120.40M |
| Capital Expenditures | $-2.34M | $-31.80M |
| Free Cash Flow | $18.54M | $44.80M |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | $-62.90M |
Short Interest & Institutional Ownership Analysis
| Metric | CLBT | FOUR |
|---|---|---|
| Shares Short | 3.63M | 11.13M |
| Short Ratio | 2.40 | 9.68 |
| Short % of Float | 0.03% | 0.17% |
| Average Daily Volume (10 Day) | 3,165,587 | 1,805,157 |
| Average Daily Volume (90 Day) | 2,043,326 | 1,982,786 |
| Shares Outstanding | 234.52M | 69.26M |
| Float Shares | 112.43M | 54.20M |
| % Held by Insiders | 0.45% | 0.02% |
| % Held by Institutions | 0.50% | 1.34% |
Dividend Analysis & Yield Comparison: Cellebrite DI vs Shift4 Payments
| Metric | CLBT | FOUR |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |